Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.74M | 8.84M | 7.39M | 4.97M | 4.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.75M | 29.96M | 29.70M | 28.01M | 28.11M |
| Operating Income | -26.75M | -29.96M | -29.70M | -28.01M | -28.11M |
| Income Before Tax | -18.21M | -23.65M | -23.63M | -34.77M | -29.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.21 | -23.65 | -23.63 | -34.77 | -29.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.21M | -23.65M | -23.63M | -34.77M | -29.40M |
| EBIT | -26.75M | -29.96M | -29.70M | -28.01M | -28.11M |
| EBITDA | -26.65M | -29.87M | -29.61M | -27.92M | -28.01M |
| EPS Basic | -2.36 | -6.52 | -8.07 | -11.28 | -10.44 |
| Normalized Basic EPS | -1.47 | -4.07 | -5.04 | -7.05 | -6.53 |
| EPS Diluted | -3.87 | -8.03 | -9.58 | -11.29 | -10.45 |
| Normalized Diluted EPS | -1.48 | -4.08 | -5.05 | -7.05 | -6.53 |
| Average Basic Shares Outstanding | 33.41M | 26.60M | 19.80M | 14.13M | 14.12M |
| Average Diluted Shares Outstanding | 33.61M | 26.81M | 20.01M | 14.13M | 14.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |